FDA Approves Novavax COVID Vaccine for High-Risk Groups
- On 19th May 2025, the FDA granted full approval to Novavax's Nuvaxovid for use in older adults and high-risk individuals, marking a major milestone for the protein-based COVID-19 vaccine.
- The U.S. Food and Drug Administration approved the Biologics License Application (BLA) for Nuvaxovid, Novavax’s COVID-19 vaccine, for adults aged 65 and older and for individuals aged 12 to 64 with at least one high-risk condition.
- Eligible high-risk conditions include asthma, cancer, diabetes, obesity, and smoking history, which increase the risk of severe COVID-19 outcomes.
- This approval triggered a $175 million milestone payment from Sanofi to Novavax, as part of their collaboration and license ....
Do You Want to Read More?
Subscribe Now
To get access to detailed content
Already a Member? Login here
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material since 2018 of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Science & Technology
- 1 India Successfully Test-Fires Prithvi-II, Agni-I and Akash Prime Missiles
- 2 Indian Navy Commissions ‘INS Nistar’
- 3 Research in Science & Tech in India
- 4 RDSNS Breakthrough Could Revolutionize Magnetometry
- 5 Vera C Rubin Observatory
- 6 WHO Recommends Injectable Lenacapavir for HIV Prevention
- 7 NASA Launches Sounding Rocket to Study Sun’s Chromosphere
- 8 Indian Navy Launches Final ASW Shallow Water Craft ‘Ajay’
- 9 Black Hole Merger Detection
- 10 Indigenous Pollution Control Vessel ‘Samudra Prachet’
